Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
Incyte (INCY) Stock Price & Analysis
1,514 Followers
INCY Stock Chart & Stats
Day’s Range$53.05 - $53.8
52-Week Range― - ―
Previous Close$53.22
Volume1.20M
Average Volume (3M)N/A
Market Cap
$11.99B
Enterprise Value$8.37B
Total Cash (Recent Filing)$3.66B
Total Debt (Recent Filing)$32.60M
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Apr 30, 2024EPS Estimate
$0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding224,526,128
10 Day Avg. Volume1,530,522
30 Day Avg. Volume1,745,178
Standard Deviation0.08
R-Squared0.17
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.46
Price to Sales (P/S)11.84
Price to Cash Flow (P/CF)20.50
P/FCF Ratio20.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.35
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda8.48
Forecast
1Y Price Target
$73.94Price Target Upside39.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Incyte News
Bulls Say, Bears Say
Bulls Say
Clinical DataClinical trials show that patients treated with Opzelura and povorcitinib experience significant improvements over placebo, highlighting the drugs' effectiveness.
Market PotentialAnalyst projects significant peak sales for topical Opzelura and oral JAK inhibitor povorcitinib, indicating a strong revenue potential overlooked by the market.
Product PipelineThe dermatology franchise is expanding with promising new data for treatments in areas with currently no approved therapy, potentially renewing revenue streams.
Bears Say
Market CompetitionAnalyst notes increasing competition from Ojjaara could impact Jakafi revenues down the line.
Patent Exclusivity ConcernsThe market continues to focus on the impending patent cliff for Incyte's key product and the absence of catalysts to protect its revenue.
Regulatory ChallengesRegulatory path for Opzelura in mild-moderate HS is unclear, posing potential challenges ahead.
---
Ownership Overview
30.68% Insiders
22.18% Mutual Funds
26.99% Other Institutional Investors
20.14% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Currently, no data Available
What is Incyte Corp’s market cap?
Currently, no data Available
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Apr 30, 2024 which is in 12 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Feb 13, 2024. The company reported $1.058 earnings per share for the quarter, missing the consensus estimate of $1.148 by -$0.09.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is $0.85.
How many shares outstanding does Incyte Corp have?
Currently, no data Available
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.058 in its last earnings report, missing expectations of $1.148. Following the earnings report the stock price went up 2.593%.
Which hedge fund is a major shareholder of Incyte Corp?
Among the largest hedge funds holding Incyte Corp’s share is Baker Bros Advisors LP. It holds Incyte Corp’s shares valued at 2B.
---
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.94 (39.04% Upside)
$73.94 (39.04% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 592.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.56%
12-Months-Change
Fundamentals
Return on Equity
12.50%
Trailing 12-Months
Asset Growth
15.96%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
---
INCY Company Deck
---
INCY Earnings Call
Q4 2024
0:00 / 0:00
---
INCY Revenue Breakdown
85.65% Product revenues, net
14.16% Product royalty revenues
0.19% Milestone and contract revenues
---
INCY Stock 12 Months Forecast
Average Price Target
$73.94
▲(39.04% Upside)
Technical Analysis
Best Analysts Covering INCY
1 Year
1 Year Success Rate
15/23 ratings generated profit
1 Year Average Return
+8.36%
reiterated a buy rating last month
Copying Marc Frahm's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +8.36% per trade.
---